about
sameAs
c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic CascadeNew antiresorptive therapies for postmenopausal osteoporosisDifferential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss.Exploring codon optimization and response surface methodology to express biologically active transmembrane RANKL in E. coli.Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitroc-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis.Ultraviolet A-induced cathepsin K expression is mediated via MAPK/AP-1 pathway in human dermal fibroblasts.Inhibition of TNF-α Reverses the Pathological Resorption Pit Profile of Osteoclasts from Patients with Acute Charcot Osteoarthropathy.Combination gene therapy targeting on interleukin-1β and RANKL for wear debris-induced aseptic loosening.Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in boneAging and bone loss: new insights for the clinician.Potential role of odanacatib in the treatment of osteoporosis.Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Investigation of the effects of estrogen on skeletal gene expression during zebrafish larval head development.Cysteine cathepsin non-inhibitory binding partners: modulating intracellular trafficking and function.Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules.Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?Protein phosphatase 2A Cα is involved in osteoclastogenesis by regulating RANKL and OPG expression in osteoblasts.Retinoic acid inhibits NFATc1 expression and osteoclast differentiation.Mediators of inflammation-induced bone damage in arthritis and their control by herbal productsDetermination of the differentiation capacities of murines' primary mononucleated cells and MC3T3-E1 cellsCathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes.In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity.Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm.Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins.Osteopetrosis
P2860
Q26998420-EDDB50E2-C8AC-4ADD-B15A-07E2FA274148Q27014775-AB4E06FE-6998-4A49-97D5-FF2280DF5137Q30415395-B446FB5B-2F21-4A9E-B845-765C9008E79CQ33583910-FAB74AF7-DCE2-4B4B-8FAE-FBCFC5FFFB90Q34948094-8C359705-DE68-4E06-BDC6-E4285A6D7011Q35034056-50E5FF85-E1A4-44E4-A662-5470783DCF4CQ35210637-91267D25-66CC-469B-BA28-7072E95B576FQ35744929-56A9E3BF-04E6-43CC-A92F-CB2C9281F397Q35951712-511F52ED-762E-4D14-A82C-B84A6DF08605Q35956822-0DBE5F8A-9F2D-4CA0-90EC-315E81E7A7AAQ36059521-3196A543-3B84-4314-874A-E6341581EE95Q36136239-5944E017-42AB-4AD2-812A-7C991301BB92Q36487636-944DA8DB-9200-4BBF-87F4-1899733C894BQ36759374-864205FD-5599-42E3-A4F2-ACE75964E2BCQ36778489-B8F70CAA-14A2-4763-9131-3313D817AFECQ36988314-3AEBCFAF-9510-4127-8976-F03B7CBB4CDCQ37056336-039C608F-090E-42B1-9826-50D7831564E1Q37058788-D0098C56-A29D-4A19-A793-C1ACCFA9967FQ37147938-8691D24E-2013-401A-B4D4-F26219A48974Q37428071-847854F5-5C9B-4530-8E06-15DE0511D059Q39238292-3A9CBB50-BDAF-4569-A184-54911E53B51AQ39579627-BD6A2FCB-3186-4123-ACAF-3B79EBE8B3E9Q41922030-6EA58313-32C1-48FA-B8A4-26AE6799D933Q42357357-5C9B3373-D36D-4595-937C-9465D975CDC0Q46908223-45805FFE-3FB8-4029-8A90-3FB84F58162FQ48109630-42B78DDA-5AE2-432D-B76A-F57D57A93BD4Q48219327-55C358AE-D17C-4EBA-ADF1-17BB2F2D7A83Q53371739-E35B82D1-6291-4301-88BA-37F946B3F123Q55724715-BC976C45-5F89-4757-AAB1-609075D48157Q56335726-010B9AF4-2486-41A5-B59D-2AD71EBA10C7
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The regulation of cathepsin K gene expression
@ast
The regulation of cathepsin K gene expression
@en
The regulation of cathepsin K gene expression
@nl
type
label
The regulation of cathepsin K gene expression
@ast
The regulation of cathepsin K gene expression
@en
The regulation of cathepsin K gene expression
@nl
altLabel
The Regulation of Cathepsin K Gene Expression
@en
prefLabel
The regulation of cathepsin K gene expression
@ast
The regulation of cathepsin K gene expression
@en
The regulation of cathepsin K gene expression
@nl
P2860
P3181
P356
P1476
The Regulation of Cathepsin K Gene Expression
@en
The regulation of cathepsin K gene expression
@en
P2093
B. R. TROEN
Bruce R Troen
P2860
P3181
P356
10.1196/ANNALS.1346.018
P407
P577
2006-04-01T00:00:00Z